Effects of bile duct ligation and cholic acid treatment on fatty liver in two rat models of non-alcoholic fatty liver disease

Digestive and Liver Disease

Volumn 44, Issue 12, 2012, Pages 1018-1026

  Gabbi, Chiara ^a   Bertolotti, Marco ^a   Anzivino, Claudia ^a   Macchioni, Daria ^a   Del Puppo, Marina ^b   Ricchi, Matteo ^a   Carubbi, Francesca ^a   Tagliafico, Enrico ^a   Romagnoli, Dante ^a   Odoardi, Maria Rosaria ^a   Loria, Paola ^a   Losi, Luisa ^c   Carulli, Nicola ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Bile acids; CYP7A1; Fatty liver; FXR; LXR

Indexed keywords

CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; CHOLIC ACID; CHOLINE; FARNESOID X RECEPTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; OXYSTEROL; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE ACID SYNTHESIS; BILE DUCT LIGATION; CHOLESTASIS; CHOLESTEROL BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOWN REGULATION; FATTY ACID SYNTHESIS; GENE EXPRESSION; GENE TARGETING; LIPID DIET; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; BIOLOGICAL MARKERS; CHOLESTEROL 7-ALPHA-HYDROXYLASE; CHOLIC ACID; COMMON BILE DUCT; DIET, HIGH-FAT; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; FATTY LIVER; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HYDROXYCHOLESTEROLS; LIGATION; LIVER; MALE; ORPHAN NUCLEAR RECEPTORS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TREATMENT OUTCOME;

EID: 84868301821     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2012.07.001     Document Type: Article

References (47)

1. Neuschwander-Tetri B.A., Caldwell S.H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003, 37:1202-1219.
2. Bedogni G., Miglioli L., Masutti F., et al. Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology 2007, 46:1387-1391.
3. Bugianesi E., Leone N., Vanni E., et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002, 123:134-140.
4. Bhala N., Angulo P., van der Poorten D., et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011, 54:1208-1216.
5. Ikemoto S., Takahashi M., Tsunoda N., et al. Cholate inhibits high-fat diet-induced hyperglycemia and obesity with acyl-CoA synthetase mRNA decrease. American Journal of Physiology 1997, 273:E37-E45.
6. Carulli N., Ponz de Leon M., Podda M., et al. Chenodeoxycholic acid and ursodeoxycholic acid effects in endogenous hypertriglyceridemias. A controlled double-blind trial. Journal of Clinical Pharmacology 1981, 21:436-442.
7. Ratziu V., de Ledinghen V., Oberti F., et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. Journal of Hepatology 2011, 54:1011-1019.
8. Angelin B., Einarsson K., Hellstrom K., Leijd B. Effects of cholestyramine and chenodeoxycholic acid on the metabolism of endogenous triglyceride in hyperlipoproteinemia. Journal of Lipid Research 1978, 19:1017-1024.
9. Grundy S.M., Ahrens E.H., Salen G. Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. Journal of Laboratory and Clinical Medicine 1971, 78:94-121.
10. Angelin B., Hershon K.S., Brunzell J.D. Bile acid metabolism in hereditary forms of hypertriglyceridemia: evidence for an increased synthesis rate in monogenic familial hypertriglyceridemia. Proceedings of the National Academy of Sciences of the United States of America 1987, 84:5434-5438.
11. Makishima M., Okamoto A.Y., Repa J.J., et al. Identification of a nuclear receptor for bile acids. Science 1999, 284:1362-1365.
12. Ma K., Saha P.K., Chan L., Moore D.D. Farnesoid X receptor is essential for normal glucose homeostasis. Journal of Clinical Investigation 2006, 116:1102-1109.
13. Watanabe M., Houten S.M., Wang L., et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. Journal of Clinical Investigation 2004, 113:1408-1418.
14. Janowski B.A., Grogan M.J., Jones S.A., et al. Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:266-271.
15. Schultz J.R., Tu H., Luk A., et al. Role of LXRs in control of lipogenesis. Genes and Development 2000, 14:2831-2838.
16. Repa J.J., Berge K.E., Pomajzl C., Richardson J.A., Hobbs H., Mangelsdorf D.J. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. Journal of Biological Chemistry 2002, 277:18793-18800.
17. Ikegami T, Hyogo H, Honda A, et al. Increased serum liver X receptor ligand oxysterols in patients with non-alcoholic fatty liver disease. Journal of Gastroenterology 2012, in press.
18. Gabbi C, Gustafsson JA. Bile acids in non-alcoholic steato-hepatitis: inserting nuclear receptors into the circle. Hepatology 2012, in press.
19. Tanaka N., Matsubara T., Krausz K.W., Patterson A.D., Gonzalez F.J. Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis. Hepatology 2012, 56:118-129.
20. Okan A., Astarcioglu H., Tankurt E., et al. Effect of ursodeoxycholic acid on hepatic steatosis in rats. Digestive Diseases and Sciences 2002, 47:2389-2397.
21. Tanaka A., Tsuneyama K., Mikami M., Uegaki S., Aiso M., Takikawa H. Gene expression profiling in whole liver of bile duct ligated rats: VEGF-A expression is up-regulated in hepatocytes adjacent to the portal tracts. Journal of Gastroenterology and Hepatology 2007, 22:1993-2000.
22. Folch J., Lees M., Sloane Stanley G.H. A simple method for the isolation and purification of total lipides from animal tissues. Journal of Biological Chemistry 1957, 226:497-509.
23. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
24. Martinez-Beamonte R., Navarro M.A., Larraga A., et al. Selection of reference genes for gene expression studies in rats. Journal of Biotechnology 2011, 151:325-334.
25. Del Puppo M., Kienle M.G., Petroni M.L., Crosignani A., Podda M. Serum 27-hydroxycholesterol in patients with primary biliary cirrhosis suggests alteration of cholesterol catabolism to bile acids via the acidic pathway. Journal of Lipid Research 1998, 39:2477-2482.
26. Alberti K.G., Zimmet P., Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 2005, 366:1059-1062.
27. Jones A.L., Hradek G.T., Renston R.H., Wong K.Y., Karlaganis G., Paumgartner G. Autoradiographic evidence for hepatic lobular concentration gradient of bile acid derivative. American Journal of Physiology 1980, 238:G233-G237.
28. Goodwin B., Jones S.A., Price R.R., et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Molecular Cell 2000, 6:517-526.
29. Maher J.J. New insights from rodent models of fatty liver disease. Antioxidants and Redox Signalling 2011, 15:535-550.
30. Lonardo A., Lombardini S., Scaglioni F., et al. Hepatic steatosis and insulin resistance: does etiology make a difference?. Journal of Hepatology 2006, 44:190-196.
31. Yang B., Brown K.K., Chen L., et al. Serum adiponectin as a biomarker for in vivo PPARgamma activation and PPARgamma agonist-induced efficacy on insulin sensitization/lipid lowering in rats. BMC Pharmacology 2004, 4:23.
32. Peet D.J., Turley S.D., Ma W., et al. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 1998, 93:693-704.
33. DeBose-Boyd R.A., Ou J., Goldstein J.L., Brown M.S. Expression of sterol regulatory element-binding protein 1c (SREBP-1c) mRNA in rat hepatoma cells requires endogenous LXR ligands. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:1477-1482.
34. Inagaki T., Choi M., Moschetta A., et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metabolism 2005, 2:217-225.
35. Russell D.W. Nuclear orphan receptors control cholesterol catabolism. Cell 1999, 97:539-542.
36. Norlin M., Andersson U., Bjorkhem I., Wikvall K. Oxysterol 7 alpha-hydroxylase activity by cholesterol 7 alpha-hydroxylase (CYP7A). Journal of Biological Chemistry 2000, 275:34046-34053.
37. Norlin M., Toll A., Bjorkhem I., Wikvall K. 24-Hydroxycholesterol is a substrate for hepatic cholesterol 7alpha-hydroxylase (CYP7A). Journal of Lipid Research 2000, 41:1629-1639.
38. Kobayashi M., Ikegami H., Fujisawa T., et al. Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 2007, 56:239-247.
39. Gilat T., Leikin-Frenkel A., Goldiner I., et al. Prevention of diet-induced fatty liver in experimental animals by the oral administration of a fatty acid bile acid conjugate (FABAC). Hepatology 2003, 38:436-442.
40. Leikin-Frenkel A., Parini P., Konikoff F.M., et al. Hypocholesterolemic effects of fatty acid bile acid conjugates (FABACs) in mice. Archives of Biochemistry and Biophysics 2008, 471:63-71.
41. Boulias K., Katrakili N., Bamberg K., Underhill P., Greenfield A., Talianidis I. Regulation of hepatic metabolic pathways by the orphan nuclear receptor SHP. EMBO Journal 2005, 24:2624-2633.
42. Huang J., Iqbal J., Saha P.K., et al. Molecular characterization of the role of orphan receptor small heterodimer partner in development of fatty liver. Hepatology 2007, 46:147-157.
43. Li T., Owsley E., Matozel M., Hsu P., Novak C.M., Chiang J.Y. Transgenic expression of cholesterol 7alpha-hydroxylase in the liver prevents high-fat diet-induced obesity and insulin resistance in mice. Hepatology 2010, 52:678-690.
44. Gustafsson J. Effect of biliary obstruction on 26-hydroxylation of C27-steroids in bile acid synthesis. Journal of Lipid Research 1978, 19:237-243.
45. Talukdar S., Bhatnagar S., Dridi S., Hillgartner F.B. Chenodeoxycholic acid suppresses the activation of acetyl-CoA carboxylase-alpha gene transcription by the liver X receptor agonist T0-901317. Journal of Lipid Research 2007.
46. Minich D.M., Havinga R., Stellaard F., Vonk R.J., Kuipers F., Verkade H.J. Intestinal absorption and postabsorptive metabolism of linoleic acid in rats with short-term bile duct ligation. American Journal of Physiology. Gastrointestinal and Liver Physiology 2000, 279:G1242-G1248.
47. Werner A., Havinga R., Bos T., Bloks V.W., Kuipers F., Verkade H.J. Essential fatty acid deficiency in mice is associated with hepatic steatosis and secretion of large VLDL particles. American Journal of Physiology. Gastrointestinal and Liver Physiology 2005, 288:G1150-G1158.